Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Adicet Bio, Inc. ACET

Healthcare  —  Biotechnology
9.02 0.75 9.07% as of 25 Sep
Market cap
$77.4M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Adicet Bio, Inc. (ACET) Business Profile

Updated before January 2025

Company Overview

Adicet Bio, Inc. (NASDAQ: ACET) is a biotechnology company specializing in the development of innovative cell therapies for cancer and other diseases. Founded in 2015, Adicet Bio is headquartered in Boston, Massachusetts, and operates with a mission to harness the power of the immune system to combat life-threatening illnesses. The company was co-founded by Aya Jakobovits, Ph.D., a pioneer in the field of immunotherapy and a key figure in the development of CAR-T cell therapies. Adicet Bio is led by a team of seasoned executives and scientists, including its CEO, Chen Schor, who brings extensive experience in biotechnology and pharmaceutical leadership. The company’s leadership team is complemented by a board of directors and scientific advisors with deep expertise in oncology, immunology, and cell therapy.

Core Business Segments

Adicet Bio focuses on the development of allogeneic gamma delta T cell therapies, a novel approach to cancer treatment. The company’s core business segments include:

1. Allogeneic Gamma Delta T Cell Therapy

Adicet Bio’s primary focus is on developing off-the-shelf gamma delta T cell therapies. Unlike traditional CAR-T therapies, which require patient-specific cell modification, Adicet’s approach uses donor-derived cells, making the process faster, more scalable, and cost-effective. Key products in this segment include:

  • ADI-001: A lead product candidate targeting CD20-positive B-cell malignancies, including non-Hodgkin’s lymphoma. ADI-001 is currently in clinical trials and has shown promising efficacy and safety results.
  • ADI-002: A preclinical candidate targeting solid tumors. ADI-002 is designed to enhance the immune response against cancer cells by leveraging gamma delta T cells’ unique properties.

2. Research and Development Services

Adicet Bio invests heavily in R&D to advance its pipeline of cell therapies. The company collaborates with academic institutions and industry partners to explore new applications for gamma delta T cells in oncology and beyond.

3. Manufacturing and Process Development

To ensure the quality and scalability of its therapies, Adicet Bio has established in-house manufacturing capabilities. The company focuses on optimizing cell expansion, genetic modification, and cryopreservation processes to deliver high-quality products to patients.

Business Model

Adicet Bio operates on a business model centered around innovation, collaboration, and commercialization. The company generates revenue through:

  • Clinical Development: Advancing its pipeline of gamma delta T cell therapies through clinical trials.
  • Partnerships and Licensing: Collaborating with pharmaceutical companies and licensing its proprietary technologies to generate milestone payments and royalties.
  • Grants and Funding: Securing funding from government agencies and non-profit organizations to support its research initiatives.

Adicet Bio’s approach integrates cutting-edge science with a patient-centric focus, aiming to deliver transformative therapies that address unmet medical needs.

Strategic Direction

Adicet Bio is committed to expanding its pipeline of gamma delta T cell therapies and exploring new therapeutic areas. Key strategic priorities include:

  • Pipeline Expansion: Advancing ADI-001 through clinical trials and initiating trials for ADI-002 and other preclinical candidates.
  • Global Reach: Establishing partnerships with international organizations to expand access to its therapies.
  • Sustainability Goals: Implementing environmentally friendly practices in its manufacturing processes and reducing its carbon footprint.
  • Innovation: Investing in next-generation technologies to enhance the efficacy and safety of its cell therapies.

Competitive Landscape

Adicet Bio operates in a highly competitive biotechnology sector, facing competition from companies developing CAR-T therapies, natural killer (NK) cell therapies, and other immunotherapies. Key competitors include:

  • Kite Pharma (a Gilead company): A leader in CAR-T cell therapy development.
  • Fate Therapeutics: Focused on developing NK cell therapies.
  • Allogene Therapeutics: Specializing in allogeneic CAR-T therapies.
  • Adaptimmune Therapeutics: Developing T-cell receptor (TCR) therapies.

Despite the competition, Adicet Bio differentiates itself through its proprietary gamma delta T cell platform, which offers unique advantages in terms of scalability, safety, and efficacy.

Risk Factors

Adicet Bio faces several risks that could impact its operations and financial performance, including:

  • Regulatory Risks: The development and approval of cell therapies are subject to stringent regulatory requirements, which could delay product launches.
  • Market Dependence: The company’s success depends on the clinical and commercial success of its lead candidates, ADI-001 and ADI-002.
  • Supply Chain Disruptions: Challenges in sourcing raw materials or manufacturing components could impact production timelines.
  • Competition: Intense competition from established players and emerging startups could limit market share.
  • Financial Risks: As a clinical-stage company, Adicet Bio relies on external funding and may face challenges in securing additional capital.

Recent Developments

Adicet Bio has made significant progress in advancing its pipeline and corporate strategy. Recent developments include:

  • Clinical Trial Updates: Positive interim results from the Phase 1 trial of ADI-001, demonstrating strong anti-tumor activity and a favorable safety profile.
  • Partnerships: Collaboration with leading academic institutions to explore new applications for gamma delta T cells.
  • Corporate Milestones: Expansion of its leadership team with key hires in clinical development and manufacturing.
  • Global Events: The COVID-19 pandemic highlighted the importance of scalable and accessible therapies, reinforcing Adicet Bio’s commitment to allogeneic approaches.

Investment Considerations

Investors considering Adicet Bio should weigh the following strengths and risks:

Strengths

  • Innovative gamma delta T cell platform with significant therapeutic potential.
  • Strong leadership team with expertise in immunotherapy and cell therapy.
  • Promising clinical data for lead candidate ADI-001.
  • Robust pipeline with opportunities for expansion into new indications.

Risks

  • Clinical and regulatory uncertainties associated with cell therapy development.
  • Dependence on a limited number of product candidates.
  • High competition in the immunotherapy space.
  • Financial risks related to funding and operational expenses.

Conclusion

Adicet Bio, Inc. is at the forefront of cell therapy innovation, leveraging its proprietary gamma delta T cell platform to develop transformative treatments for cancer and other diseases. With a strong pipeline, experienced leadership, and a commitment to innovation, the company is well-positioned to address unmet medical needs and drive future growth. However, investors should carefully consider the risks associated with clinical-stage biotechnology companies before making investment decisions.